Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiomax in HIT/HITTS Patients Undergoing Cardiac Surgery
NCT00079508Phase 3Completed
- Sponsor
- The Medicines Company
- Start
- Apr 2004
- Primary completion
- Oct 2005
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bivalirudin in heparin-induced thrombocytopenia (HIT), sponsored by The Medicines Company. Started Apr 2004; status: completed.
02
Drugs
bivalirudin
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on NCT00079508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00079508.